Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Cefazolin sodium
All injection strengths: not a benefit
Cefazolin for Injection · DIN 02108127 · 1 g/Vial · powder for injection, vial
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Cefazolin
Brand(s): Many Generic Brands
DOSAGE FORM/ STRENGTH: 1 g/vial Injection
For treatment of infections susceptible to cefazolin.
Standard Approval Duration: As requested up to 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Cefazolin for Injection · DIN 02108127
Manufacturer: Teva Canada Limited; listing date 2010-06-14
Health Canada: Marketed since 2013-04-13 · brand CEFAZOLIN FOR INJECTION · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 1 G/VIAL · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCefazolin for Injection: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02108127)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02108127).
DIN 02108127: Cefazolin for Injection
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 081228103; group id 37; item number 0074; lccId None; manufacturer id TEV
Source form: Inj Pd-Vial Pk; strength: 1g/Vial
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02108127
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19532
Interchangeable products
Cefazolin for Injection · DIN 02297205 · $6.0000
Cefazolin for Injection · DIN 02437112 · $6.0000
Cefazolin for Injection USP · DIN 02308959 · $6.0000
Cefazolin for Injection USP · DIN 02465469 · $6.0000
Shortage status: resolved shortage (ended August 3, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02108127
Shortage record checked October 6, 2026
Cefazolin for Injection · DIN 02437112 · 1 g/Vial · powder for injection, vial
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Cefazolin
Brand(s): Many Generic Brands
DOSAGE FORM/ STRENGTH: 1 g/vial Injection
For treatment of infections susceptible to cefazolin.
Standard Approval Duration: As requested up to 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Cefazolin for Injection · DIN 02437112
Manufacturer: Sterimax Inc.; listing date 2022-01-31
Health Canada: Marketed since 2023-12-21 · brand CEFAZOLIN FOR INJECTION · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous, Intramuscular · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 1 G/VIAL · company Hikma canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCefazolin for Injection: Formulary list price $6.00 per unit (the source does not state the unit; exact figure $6.0000). What the ministry pays, not the patient.
Ministry pays: $6.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02437112)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02437112).
DIN 02437112: Cefazolin for Injection
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 081228103; group id 37; item number 0074; lccId None; manufacturer id STE
Source form: Inj Pd-Vial Pk; strength: 1g/Vial
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $6.0000; ministry $6.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02437112
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92142
Interchangeable products
Cefazolin for Injection · DIN 02108127 · not recorded
Cefazolin for Injection · DIN 02297205 · $6.0000
Cefazolin for Injection USP · DIN 02308959 · $6.0000
Cefazolin for Injection USP · DIN 02465469 · $6.0000
Shortage status: resolved shortage (ended May 5, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02437112
Shortage record checked October 6, 2026
Cefazolin for Injection USP · DIN 02308959 · 1 g/Vial · powder for injection, vial
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Cefazolin
Brand(s): Many Generic Brands
DOSAGE FORM/ STRENGTH: 1 g/vial Injection
For treatment of infections susceptible to cefazolin.
Standard Approval Duration: As requested up to 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Cefazolin for Injection USP · DIN 02308959
Manufacturer: Sandoz Canada Inc.; listing date 2023-10-31
Health Canada: Marketed since 2008-04-18 · brand CEFAZOLIN FOR INJECTION USP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous, Intramuscular · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 1 G/VIAL · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCefazolin for Injection USP: Formulary list price $6.00 per unit (the source does not state the unit; exact figure $6.0000). What the ministry pays, not the patient.
Ministry pays: $6.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02308959)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02308959).
DIN 02308959: Cefazolin for Injection USP
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 081228103; group id 37; item number 0074; lccId None; manufacturer id SDZ
Source form: Inj Pd-Vial Pk; strength: 1g/Vial
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $6.0000; ministry $6.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02308959
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79456
Interchangeable products
Cefazolin for Injection · DIN 02108127 · not recorded
Cefazolin for Injection · DIN 02297205 · $6.0000
Cefazolin for Injection · DIN 02437112 · $6.0000
Cefazolin for Injection USP · DIN 02465469 · $6.0000
Shortage status: shortage reported ended October 5, 2026 (report last updated October 5, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02308959
Shortage record checked October 6, 2026
Cefazolin for Injection USP · DIN 02465469 · 1 g/Vial · powder for injection, vial
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Cefazolin
Brand(s): Many Generic Brands
DOSAGE FORM/ STRENGTH: 1 g/vial Injection
For treatment of infections susceptible to cefazolin.
Standard Approval Duration: As requested up to 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Cefazolin for Injection USP · DIN 02465469
Manufacturer: Sterimax Inc.; listing date 2023-09-28
Health Canada: Marketed since 2023-06-06 · brand CEFAZOLIN SODIUM FOR INJECTION BP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 1 G/VIAL · company Sterimax inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCefazolin for Injection USP: Formulary list price $6.00 per unit (the source does not state the unit; exact figure $6.0000). What the ministry pays, not the patient.
Ministry pays: $6.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02465469)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02465469).
DIN 02465469: Cefazolin for Injection USP
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 081228103; group id 37; item number 0074; lccId None; manufacturer id STE
Source form: Inj Pd-Vial Pk; strength: 1g/Vial
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $6.0000; ministry $6.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02465469
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95364
Interchangeable products
Cefazolin for Injection · DIN 02108127 · not recorded
Cefazolin for Injection · DIN 02297205 · $6.0000
Cefazolin for Injection · DIN 02437112 · $6.0000
Cefazolin for Injection USP · DIN 02308959 · $6.0000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02465469
Shortage record checked October 6, 2026
Cefazolin for Injection · DIN 02437120 · 10 g/Vial · powder for injection, vial
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Cefazolin
Brand(s): Many Generic Brands
DOSAGE FORM/ STRENGTH: 1 g/vial Injection
For treatment of infections susceptible to cefazolin.
Standard Approval Duration: As requested up to 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection · DIN 02437120
Manufacturer: Sterimax Inc.; listing date 2022-01-31
Health Canada: Marketed since 2024-02-14 · brand CEFAZOLIN FOR INJECTION · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 10 G/VIAL · company Hikma canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCefazolin for Injection: Formulary list price $56.00 per unit (the source does not state the unit; exact figure $56.0000). What the ministry pays, not the patient.
Ministry pays: $56.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02437120)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02437120).
DIN 02437120: Cefazolin for Injection
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 081228122; group id 37; item number 0075; lccId None; manufacturer id STE
Source form: Inj Pd-Vial Pk; strength: 10g/Vial
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $56.0000; ministry $56.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02437120
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92143
Interchangeable products
Cefazolin for Injection · DIN 02108135 · not recorded
Cefazolin for Injection · DIN 02297213 · $56.0000
Cefazolin for Injection USP · DIN 02308967 · $56.0000
Cefazolin for Injection USP · DIN 02465477 · $56.0000
Shortage status: resolved shortage (ended June 30, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02437120
Shortage record checked October 6, 2026
Cefazolin for Injection USP · DIN 02308967 · 10 g/Vial · powder for injection, vial
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Cefazolin
Brand(s): Many Generic Brands
DOSAGE FORM/ STRENGTH: 1 g/vial Injection
For treatment of infections susceptible to cefazolin.
Standard Approval Duration: As requested up to 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection USP · DIN 02308967
Manufacturer: Sandoz Canada Inc.; listing date 2023-10-31
Health Canada: Marketed since 2008-04-18 · brand CEFAZOLIN FOR INJECTION USP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 10 G/VIAL · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCefazolin for Injection USP: Formulary list price $56.00 per unit (the source does not state the unit; exact figure $56.0000). What the ministry pays, not the patient.
Ministry pays: $56.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02308967)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02308967).
DIN 02308967: Cefazolin for Injection USP
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 081228122; group id 37; item number 0075; lccId None; manufacturer id SDZ
Source form: Inj Pd-Vial Pk; strength: 10g/Vial
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $56.0000; ministry $56.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02308967
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79457
Interchangeable products
Cefazolin for Injection · DIN 02108135 · not recorded
Cefazolin for Injection · DIN 02297213 · $56.0000
Cefazolin for Injection · DIN 02437120 · $56.0000
Cefazolin for Injection USP · DIN 02465477 · $56.0000
Shortage status: resolved shortage (ended April 13, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02308967
Shortage record checked October 6, 2026
Cefazolin for Injection USP · DIN 02465477 · 10 g/Vial · powder for injection, vial
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Cefazolin
Brand(s): Many Generic Brands
DOSAGE FORM/ STRENGTH: 1 g/vial Injection
For treatment of infections susceptible to cefazolin.
Standard Approval Duration: As requested up to 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection USP · DIN 02465477
Manufacturer: Sterimax Inc.; listing date 2023-09-28
Health Canada: Marketed since 2023-06-06 · brand CEFAZOLIN SODIUM FOR INJECTION BP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 10 G/VIAL · company Sterimax inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCefazolin for Injection USP: Formulary list price $56.00 per unit (the source does not state the unit; exact figure $56.0000). What the ministry pays, not the patient.
Ministry pays: $56.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02465477)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02465477).
DIN 02465477: Cefazolin for Injection USP
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 081228122; group id 37; item number 0075; lccId None; manufacturer id STE
Source form: Inj Pd-Vial Pk; strength: 10g/Vial
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $56.0000; ministry $56.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02465477
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95365
Interchangeable products
Cefazolin for Injection · DIN 02108135 · not recorded
Cefazolin for Injection · DIN 02297213 · $56.0000
Cefazolin for Injection · DIN 02437120 · $56.0000
Cefazolin for Injection USP · DIN 02308967 · $56.0000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02465477
Shortage record checked October 6, 2026
Cefazolin for Injection, USP · DIN 02237140 · 10 g/Vial · powder for injection, vial (Preservative-Free)
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Cefazolin
Brand(s): Many Generic Brands
DOSAGE FORM/ STRENGTH: 1 g/vial Injection
For treatment of infections susceptible to cefazolin.
Standard Approval Duration: As requested up to 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection, USP · DIN 02237140
Manufacturer: Fresenius Kabi Canada Ltd.; listing date 2025-08-29
Health Canada: Marketed since 2016-01-13 · brand CEFAZOLIN FOR INJECTION, USP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 10 G/VIAL · company Fresenius kabi canada ltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCefazolin for Injection, USP: Formulary list price $56.00 per unit (the source does not state the unit; exact figure $56.0000). What the ministry pays, not the patient.
Ministry pays: $56.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02237140)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02237140).
DIN 02237140: Cefazolin for Injection, USP
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 081228194; group id 37; item number 0076; lccId None; manufacturer id FKC
Source form: Inj Pd-Vial Pk (Preservative-Free); strength: 10g/Vial
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $56.0000; ministry $56.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02237140
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60455
Interchangeable products
Ancef · DIN 01919628 · not recorded
Shortage status: resolved shortage (ended July 6, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02237140
Shortage record checked October 6, 2026
Cefazolin for Injection · DIN 02108119 · 500 mg/Vial · powder for injection, vial
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Cefazolin
Brand(s): Many Generic Brands
DOSAGE FORM/ STRENGTH: 1 g/vial Injection
For treatment of infections susceptible to cefazolin.
Standard Approval Duration: As requested up to 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection · DIN 02108119
Manufacturer: Teva Canada Limited; listing date 2022-01-31
Health Canada: Marketed since 2013-04-13 · brand CEFAZOLIN FOR INJECTION · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous, Intramuscular · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 500 MG/VIAL · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCefazolin for Injection: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02108119)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02108119).
DIN 02108119: Cefazolin for Injection
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 081228112; group id 37; item number 0073; lccId None; manufacturer id TEV
Source form: Inj Pd-Vial Pk; strength: 500mg/Vial
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02108119
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19521
Interchangeable products
Cefazolin for Injection · DIN 02437104 · $4.0000
Cefazolin for Injection USP · DIN 02308932 · $4.0000
Shortage status: discontinued (July 31, 2019, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02108119
Shortage record checked October 6, 2026
Cefazolin for Injection · DIN 02437104 · 500 mg/Vial · powder for injection, vial
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Cefazolin
Brand(s): Many Generic Brands
DOSAGE FORM/ STRENGTH: 1 g/vial Injection
For treatment of infections susceptible to cefazolin.
Standard Approval Duration: As requested up to 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection · DIN 02437104
Manufacturer: Sterimax Inc.; listing date 2022-01-31
Health Canada: Marketed since 2025-02-06 · brand CEFAZOLIN FOR INJECTION · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous, Intramuscular · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 500 MG/VIAL · company Hikma canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCefazolin for Injection: Formulary list price $4.00 per unit (the source does not state the unit; exact figure $4.0000). What the ministry pays, not the patient.
Ministry pays: $4.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02437104)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02437104).
DIN 02437104: Cefazolin for Injection
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 081228112; group id 37; item number 0073; lccId None; manufacturer id STE
Source form: Inj Pd-Vial Pk; strength: 500mg/Vial
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $4.0000; ministry $4.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02437104
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92141
Interchangeable products
Cefazolin for Injection · DIN 02108119 · not recorded
Cefazolin for Injection USP · DIN 02308932 · $4.0000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02437104
Shortage record checked October 6, 2026
Cefazolin for Injection USP · DIN 02308932 · 500 mg/Vial · powder for injection, vial
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Cefazolin
Brand(s): Many Generic Brands
DOSAGE FORM/ STRENGTH: 1 g/vial Injection
For treatment of infections susceptible to cefazolin.
Standard Approval Duration: As requested up to 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection USP · DIN 02308932
Manufacturer: Sandoz Canada Inc.; listing date 2023-10-31
Health Canada: Marketed since 2008-04-18 · brand CEFAZOLIN FOR INJECTION USP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 500 MG/VIAL · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCefazolin for Injection USP: Formulary list price $4.00 per unit (the source does not state the unit; exact figure $4.0000). What the ministry pays, not the patient.
Ministry pays: $4.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02308932)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02308932).
DIN 02308932: Cefazolin for Injection USP
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 081228112; group id 37; item number 0073; lccId None; manufacturer id SDZ
Source form: Inj Pd-Vial Pk; strength: 500mg/Vial
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $4.0000; ministry $4.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02308932
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79454
Interchangeable products
Cefazolin for Injection · DIN 02108119 · not recorded
Cefazolin for Injection · DIN 02437104 · $4.0000
Shortage status: resolved shortage (ended January 8, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02308932
Shortage record checked October 6, 2026
Cefazolin for Injection · DIN 02297205 · 1 g/Vial · powder for injection, vial
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.Discontinued June 28, 2019 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗); Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list. Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Cefazolin
Brand(s): Many Generic Brands
DOSAGE FORM/ STRENGTH: 1 g/vial Injection
For treatment of infections susceptible to cefazolin.
Standard Approval Duration: As requested up to 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
Cefazolin for Injection · DIN 02297205
Manufacturer: Orchid Healthcare; listing date 2010-06-14
Health Canada: Cancelled post market since 2019-06-28 · brand CEFAZOLIN FOR INJECTION USP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous, Intramuscular · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 1 G/VIAL · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCefazolin for Injection: Formulary list price $6.00 per unit (the source does not state the unit; exact figure $6.0000). What the ministry pays, not the patient.
Ministry pays: $6.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02297205)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02297205).
DIN 02297205: Cefazolin for Injection
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 081228103; group id 37; item number 0074; lccId None; manufacturer id ORC
Source form: Inj Pd-Vial Pk; strength: 1g/Vial
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $6.0000; ministry $6.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02297205
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78258
Interchangeable products
Cefazolin for Injection · DIN 02108127 · not recorded
Cefazolin for Injection · DIN 02437112 · $6.0000
Cefazolin for Injection USP · DIN 02308959 · $6.0000
Cefazolin for Injection USP · DIN 02465469 · $6.0000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02297205
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 28, 2019 — choose a marketed DIN from the same-category list.
Cefazolin for Injection · DIN 02108135 · 10 g/Vial · powder for injection, vial
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-27 — choose a marketed DIN from the same-category list.Discontinued September 27, 2022 · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-27 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-09-27 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Cefazolin
Brand(s): Many Generic Brands
DOSAGE FORM/ STRENGTH: 1 g/vial Injection
For treatment of infections susceptible to cefazolin.
Standard Approval Duration: As requested up to 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection · DIN 02108135
Manufacturer: Teva Canada Limited; listing date 2010-06-14
Health Canada: Cancelled post market since 2022-09-27 · brand CEFAZOLIN FOR INJECTION · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 10 G/VIAL · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCefazolin for Injection: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02108135)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02108135).
DIN 02108135: Cefazolin for Injection
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 081228122; group id 37; item number 0075; lccId None; manufacturer id TEV
Source form: Inj Pd-Vial Pk; strength: 10g/Vial
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02108135
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19534
Interchangeable products
Cefazolin for Injection · DIN 02297213 · $56.0000
Cefazolin for Injection · DIN 02437120 · $56.0000
Cefazolin for Injection USP · DIN 02308967 · $56.0000
Cefazolin for Injection USP · DIN 02465477 · $56.0000
Shortage status: discontinued (March 31, 2023, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02108135
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 27, 2022 — choose a marketed DIN from the same-category list.
Cefazolin for Injection · DIN 02297213 · 10 g/Vial · powder for injection, vial
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.Discontinued June 28, 2019 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Cefazolin
Brand(s): Many Generic Brands
DOSAGE FORM/ STRENGTH: 1 g/vial Injection
For treatment of infections susceptible to cefazolin.
Standard Approval Duration: As requested up to 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Cefazolin for Injection · DIN 02297213
Manufacturer: Orchid Healthcare; listing date 2010-06-14
Health Canada: Cancelled post market since 2019-06-28 · brand CEFAZOLIN FOR INJECTION USP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 10 G/VIAL · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCefazolin for Injection: Formulary list price $56.00 per unit (the source does not state the unit; exact figure $56.0000). What the ministry pays, not the patient.
Ministry pays: $56.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02297213)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02297213).
DIN 02297213: Cefazolin for Injection
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 081228122; group id 37; item number 0075; lccId None; manufacturer id ORC
Source form: Inj Pd-Vial Pk; strength: 10g/Vial
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $56.0000; ministry $56.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02297213
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78259
Interchangeable products
Cefazolin for Injection · DIN 02108135 · not recorded
Cefazolin for Injection · DIN 02437120 · $56.0000
Cefazolin for Injection USP · DIN 02308967 · $56.0000
Cefazolin for Injection USP · DIN 02465477 · $56.0000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02297213
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 28, 2019 — choose a marketed DIN from the same-category list.
Ancef · DIN 01919628 · 10 g/Vial · powder for injection, vial (Preservative-Free)
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2000-07-25 — choose a marketed DIN from the same-category list.Discontinued July 25, 2000 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2000-07-25 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-07-25 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access criteria on record are for Brand(s): Many Generic Brands; DOSAGE FORM/ STRENGTH: 1 g/vial Injection — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Cefazolin
Brand(s): Many Generic Brands
DOSAGE FORM/ STRENGTH: 1 g/vial Injection
For treatment of infections susceptible to cefazolin.
Standard Approval Duration: As requested up to 5 years
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 462, record 297, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Ancef · DIN 01919628
Manufacturer: Smith Kline Beecham Pharma Inc; listing date 2025-08-29
Health Canada: Cancelled post market since 2000-07-25 · brand ANCEF INJ PWS 10GM/VIAL USP · ATC J01DB04 CEFAZOLIN · form Powder for solution · route Intravenous · ingredients CEFAZOLIN (CEFAZOLIN SODIUM) 10 G/VIAL · company Smithkline beecham pharma division of smithkline beecham inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAncef: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01919628)
Source record
DIN 01919628: Ancef
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081228194; group id 37; item number 0076; lccId None; manufacturer id SMJ
Source form: Inj Pd-Vial Pk (Preservative-Free); strength: 10g/Vial
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01919628
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12914
Interchangeable products
Cefazolin for Injection, USP · DIN 02237140 · $56.0000
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01919628
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 25, 2000 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (J01D, J01DB): coverage varies; not interchangeable
- Cefadroxil (Duricef): general benefit, not a benefit
- Cephalexin (Ceporex): general benefit, not a benefit
- Cefixime (Suprax): general benefit
- Cefprozil (Ran-Cefprozil): general benefit, not a benefit
- Ceftriaxone (Rocephin): general benefit, not a benefit
- Cefuroxime axetil (Ceftin): general benefit, not a benefit
1 more in the class list below
Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered
Matched class: 08:12:28 Other Antibiotics
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE
Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, TOBRAMYCIN, TOBRAMYCIN SULFATE
08:12:28 Other Antibiotics
· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap
· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab
· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab
· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab
· 16 products · Listed, not a benefit (3), General benefit (9), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk
· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab
· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial, 2g/Vial · Inj Pd-Vial Pk
· 22 products · Listed, not a benefit (2), General benefit (20) · strengths: 150mg, 300mg · Cap
· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp
· 3 products ·
Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk
· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk
· 1 products ·
Limited Use, codes 677 · strengths: 500mg/Vial · Pd for Sol (Preservative-Free)
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:28
and 4 more
Full class listing
Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles
Same formulary class, not same indication: class membership alone does not establish equivalent uses.